Long-term Cost-Effectiveness of Insertion of a Biological Mesh During Stoma-Site Closure: 5-8-year Follow-Up of the ROCSS Randomized Controlled Trial
Mark Monahan,Manjinder Kaur,Tracy Roberts,Lorraine R. Munetsi,Ellen Jerome,Laura Magill,Ruth Evans,Siobhan Mackay,Mathew Popplewell,Alasdair Ball,Rebecca Griggs,Jamshed Shabbir,Ahmed Ebrahim,Toby Hammond,Vibha Ramesh,Talakalukoppa Amarnath,Olivia O'Connor,Evripidis Tokidis,Michael Pierson,Peter Webster,Tim Wilson,George Davis,Mark Doyle,Benjamin Finch,Anuj Gupta,Denise Hill,Michael Popoola,Andrew Rees,Lisa Santos,Benjamin Stubbs,Maddy Taylor,Gakul Bhatta,Christopher Liao,Adeline Rankin,Elva Wilhelmsen,James Blackwell,Elisa Lenzi,Nicholas Watson,Jill Cooke,Chloe Hardy,Franscois Runau,James Wolff,Farhat Amir,Phillippa Hill,Chris J. Smart,Zoe Gates,Nuha Yassin,Rosie Holdsworth,Ami Mishra,Mohamed Rabie,Kimberley Netherton,Milind Rao,Adam Walsh,Dibyendu Bandyopadhyay,Christopher Barr,Kay Kell,Agnieszka Tulwin,Lucy Pippard,Samir Mehta,James Glasbey,Sue Jowett,Dion Morton,Thomas Pinkney,Kelly Handley,James Brown,Richard Wilkin,Aneel Bhangu,Amani Asour,Sudhakar Mangam,Austin Acheson,James Ng,Jaspreet Seehra,Hersham Elhakim,Angus Watson,Marius Paraoan,Amal Singh,Claire Williams,Rebecca Lefroy,Neil Yeomans,Joyce Katebe,Emily Wales,Julian Zeolla,Graham Branagan,Alistair Shaw,Charles West,Julie Colley,Samerah Saeed,Andrew Torrance,Anthony Antoniou,Manisha Baden,Yolanda Baird,Bruce Levy,Erikka Siddall,Ankita Sunny,Yvette Thirwall,Ester Towner,Manijeh Ghods,Bridget Hopkins,Sharad Karandikar,Harvi Mann,Arlo Whitehouse,Healther Willis,Marriam Ahmed,Abhilasha Patel,Jessica Rayer,Nigel Williams,Elizabeth Baker,Deborah Wilson,Deborah Nicol,Sarah Duff,Mary Kumarendran,Iona Pearson,Nader Francis
DOI: https://doi.org/10.1093/bjs/znae159
2024-01-01
Abstract:Background The original ROCSS trial demonstrated a significant reduction in clinically detectable incisional hernias at 2 years in patients receiving prophylactic biological mesh during stoma closure. ROCSS-Ex was designed to investigate the 5-8-year cost-effectiveness of mesh in the surviving cohort using an abdominal wall-specific quality of life score.Methods Eligible participants from original UK centres were identified. The primary outcome (abdominal wall-specific quality of life) was measured using the HerQLes score and EQ-5D-5L. Assessors remained blind to patients' original allocation, even if the patient was aware of their treatment.Results Of the original 790 patients, 598 were available for long-term follow-up. HerQLes scores were available for 396 patients (no mesh: 191, mesh: 205). There was no difference in primary outcome between the two groups (mean difference of 1.48, 95% c.i. (-2.35, 5.32), P = 0.45) and no cost benefit of routine insertion of prophylactic biological mesh across the entire cohort in the long term. However, patients who received mesh experienced significantly fewer stoma site complications within the first 3 years after reversal and needed fewer surgical reinterventions (32 versus 54 for the no mesh group; incidence rate ratio of 0.55, 95% c.i. (0.31, 0.97), P = 0.04).Conclusions ROCSS-Ex has shown equivocal outcomes for prophylactic mesh insertion versus standard repair on abdominal wall-specific quality of life 5-8 years after surgery. As most reinterventions occurred within the first 3 years post-surgery, there may be a role for prophylactic mesh in a subset of patients who would be most adversely affected by repeated surgery early on.Trial Registration ISRCTN25584182 (http://www.clinicaltrials.gov). ROCSS-Ex has shown that routine prophylactic mesh insertion had no cost benefit compared to standard repair in long-term follow-up after stoma reversal. However, as most reinterventions occurred within the first 3 years post-surgery, there may be a role for prophylactic mesh in a subset of patients who would benefit most from a rapid recovery.